Renal diseases

Anesthesia and Uncommon Diseases

Volumn , Issue , 2006, Pages 229-260

  Cereda, Maurizio ^a   Horak, Jiri ^a   Neligan, Patrick ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79956361095     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141602212-1.50010-X     Document Type: Chapter

References (215)

1. Brezis M, Heyman SN, Dinour D, et al. Role of nitric oxide in renal medullary oxygenation: Studies in isolated and intact rat kidneys. J Clin Invest 1991, 88:390-395.
2. Thurau K, Boylan JW Acute renal success: The unexpected logic of oliguria in acute renal failure. Am J Med 1976, 61:301-308.
3. Brezis M, Rosen S Hypoxia of the renal medulla its implications for disease. N Engl J Med 1995, 332:647-655.
4. Heyman SN, Rosen S, Epstein FH, et al. Loop diuretics reduce hypoxic damage to proximal tubules of the isolated perfused rat kidney. Kidney Int 1994, 45:981-985.
5. Cantarovich F, Rangoonwala B, Lorenz H, et al. High-dose furosemide for established ARF: A prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004, 44:402-409.
6. U.S. Renal Data Systems. USRDS 1997 annual data report April 1997, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
7. Pollock C, Lui P-L, Gyory AZ, et al. Dysmorphism of urinary red blood cells value in diagnosis. Kidney Int 1989, 36:1045-1049.
8. Cibrik DM, Sedor JR Immunopathogenesis of renal disease. Primer on Kidney Diseases 1997, 141-149. Academic Press, San Diego, CA. 2nd ed. A. Greenberg (Ed.).
9. Hricik DE, Chung-Park M, Sedor JR Glomerulonephritis. N Engl J Med 1998, 339:888-899.
10. Emancipator SN IgA nephropathy: Morphologic expression and pathogenesis. Am J Kidney Dis 1994, 23:451-462.
11. Julian BA, Waldo FB, Rifai A, Mestecky J IgA nephropathy, the most common glomerulonephritis worldwide: A neglected disease in the United States?. Am J Med 1988, 84:129-132.
12. Davin J-C, Ten Berge IJ, Weeing JJ What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis?. Kidney Int 2001, 59:823-834.
13. Holm SE The pathogenesis of acute post-streptococcal glomerulonephritis in new lights. APMIS 1988, 96:189-193.
14. Tejani A, Ingulli E Poststreptococcal glomerulonephritis: Current clinical and pathologic concepts. Nephron 1990, 55:1-5.
15. Rodríguez-Iturbe B, García R Isolated glomerular diseases: Acute glomerulonephritis. Pediatric Nephrology 1987, 407-419. Williams & Wilkins, Baltimore. 2nd ed. M.A. Holliday, T.M. Barratt, R.L. Vernier (Eds.).
16. Schacht RG, Gluck MC, Gallo GR, Baldwin DS Progression to uremia after remission of acute poststreptococcal glomerulonephritis. N Engl J Med 1976, 295:977-981.
17. Roy S, Pitcock JA, Etteldorf JN Prognosis of acute poststreptococcal glomerulonephritis in childhood: Prospective study and review of the literature. Adv Pediatr 1976, 23:35-69.
18. Kerr PG, Lan HY, Atkins RC Rapidly progressive glomerulonephritis. Diseases of the Kidney 1997, vol 2:1619-1644. Little, Brown, Boston. 6th ed. R.W. Schrier, C.W. Gottschalk (Eds.).
19. Bolton WK Rapidly progressive glomerulonephritis. Semin Nephrol 1996, 16:517-526.
20. Merkel F, Pullig O, Marx M, et al. Course and prognosis of anti-basement membrane antibody mediated disease: Report of 35 cases. Nephrol Dial Transplant 1994, 9:372-376.
21. Hogan SL, Nachman PH, Wilkman AS, et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:23-32.
22. Lal DPSS, O'Donoghue DJ, Haeney M Effect of diagnostic delay on disease severity and outcome in glomerulonephritis caused by anti-neutrophil cytoplasmic antibodies. J Clin Pathol 1996, 49:942-944.
23. Heilman RL, Offord KP, Holley KE, Velosa JA Analysis of risk factors for patient and renal survival in crescentic glomerulonephritis. Am J Kidney Dis 1987, 9:98-107.
24. Nachman PH, Hogan SL, Jennette JC, Falk RJ Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:33-39.
25. Levy JB, Pusey CD Still a role for plasma exchange in rapidly progressive glomerulonephritis?. J Nephrol 1997, 10:7-13.
26. Madaio MP, Harrington JT The diagnosis of glomerular diseases: Acute glomerulonephritis and the nephrotic syndrome. Arch Intern Med 2001, 161:25-34.
27. Baldwin DS, Gluck MC, Lowenstein J, Gallo GR Lupus nephritis: Clinical course as related to morphologic forms and their transitions. Am J Med 1977, 62:12-30.
28. Hricik DE, Kassirer JP The nephrotic syndrome. Dis Mon 1982, 28:1-56.
29. Haas M, Meehan SM, Karrison TG, Spargo BH Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997, 30:621-631.
30. Johnson RJ, Feehally J Comprehensive Clinical Nephrology 2003, xvii. Mosby, St. Louis, 1229.
31. Johnson RJ, Willson R, Yamabe H, et al. Renal manifestations of hepatitis C virus infection. Kidney Int 1994, 46:1255-1263.
32. Schrier RW, Fassett RG A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 1998, 53:1111-1117.
33. Orth SR, Ritz E The nephrotic syndrome. N Engl J Med 1998, 338:1202-1211.
34. Brater DC Diuretic therapy. N Engl J Med 1998, 339:387-395.
35. Bellomo R, Atkins RC Membranous nephropathy and thromboembolism: Is prophylactic anticoagulation warranted?. Nephron 1993, 63:249-254.
36. DeBroe ME, Elseviers MM Analgesic nephropathy. N Engl J Med 1998, 338:446-452.
37. Scheinman SJ, Guay-Woodford LM, Thakker RV, et al. Genetic disorders of renal electrolyte transport. N Engl J Med 1999, 340:1177-1187.
38. Gahl WA, Thoene JG, Schneider JA Cystinosis. N Engl J Med 2002, 347:111-121.
39. Rodriguez-Soriano J New insights into the pathogenesis of renal tubular acidosis from functional to molecular studies. Pediatr Nephrol 2000, 14:1121-1136.
40. Fencl V, Leith DE Stewart's quantitative acid-base chemistry: Applications in biology and medicine. Respir Physiol 1993, 91:1-16.
41. Corey HE Stewart and beyond: New models of acid-base balance. Kidney Int 2003, 64:777-787.
42. --transporting epithelia. Proc Natl Acad Sci U S A 2003, 100:663-668.
43. Shaer AJ Inherited primary renal tubular hypokalemic alkalosis: A review of Gitelman and Bartter syndromes. Am J Med Sci 2001, 322:316-332.
44. Igarashi T, Inatomi J, Sekine T, et al. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet 1999, 23:264-266.
45. Sabatini S, Kurtzman NA Biochemical and genetic advances in distal renal tubular acidosis. Semin Nephrol 2001, 21:94-106.
46. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293:1107-1112.
47. Wilson PD Polycystic kidney disease. N Engl J Med 2004, 350:151-164.
48. Levey AS Clinical practice: Nondiabetic kidney disease. N Engl J Med 2002, 347:1505-1511.
49. Palmer BF Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002, 347:1256-1261.
50. Remuzzi G, Bertani T Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448-1456.
51. Riz E, Orth SR Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999, 341:1127-1133.
52. Rossing P, Hommel E, Smidt UM, Parving HH Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993, 42:715-719.
53. Ravid M, Brosh D, Ravid-Safran D, et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998, 158:998-1004.
54. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
55. Nielsen FS, Rossing P, Gall MA, et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997, 46:1182-1188.
56. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754-762.
57. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999, 354:359-364.
58. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941-1951.
59. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
60. Firth PG, Head CA Sickle cell disease and anesthesia. Anesthesiology 2004, 101:766-785.
61. Harding MB, Smith LR, Himmelstein SI, et al. Renal artery stenosis: Prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992, 2:1608-1616.
62. Safian RD, Textor SC Renal-artery stenosis. N Engl J Med 2001, 344:431-442.
63. Slovut DP, Olin JW Fibromuscular dysplasia. N Engl J Med 2004, 350:1862-1871.
64. Zeller T, Frank U, Muller C, et al. Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. Circulation 2003, 108:2244-2249.
65. Levey A Clinical practice: Nondiabetic kidney disease. N Engl J Med 2002, 347:1505-1511.
66. Centers for Disease Control and Prevention State-specific trends in chronic kidney failure United States, 1990-2001. MMWR Morbid Mortal Wkly Rep 2004, 53:918-920.
67. Incidence and prevalence of ESRD. United States Renal Data System. Am J Kidney Dis 1998, 32(2 Suppl 1):S38-S49.
68. Clase CM, Garg AX, Kibert BA Classifying kidney problems: Can we avoid framing risks as diseases?. BMJ 2004, 329:912-915.
69. Kellerman PS Perioperative care of the renal patient. Arch Intern Med 1994, 154:1674-1688.
70. Parmar MS Chronic renal disease. BMJ 2002, 325:85-90.
71. Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant 1996, 11:461-467.
72. Remuzzi G, Bertani T Pathophysiology of progressive nephropathies. N Engl J Med 1998, 339:1448-1456.
73. Rossing P, Hommel E, Smidt UM, Parving HH Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993, 42:715-719.
74. Johnson RJ, Feehally J Comprehensive Clinical Nephrology 2003, xvii. Mosby, St. Louis, 1229.
75. Foley RN, Parfrey PS, Sarnak MJ Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998, 9(12 Suppl):S16-S23.
76. Ifudu O Care of patients undergoing hemodialysis. N Engl J Med 1998, 339:1054-1062.
77. Gupta R, Birnbaum Y, et al. The renal patient with coronary artery disease: Current concepts and dilemmas. J Am Coll Cardiol 2004, 44:1343-1353.
78. Steiner RW, Coggins C, Carvalho AC Bleeding time in uremia: A useful test to assess clinical bleeding. Am J Hematol 1979, 7:107-117.
79. De Lima JJ, Sabbaga E, Vieira ML, et al. Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing. Hypertension 2003, 42:263-268.
80. Lewis MS, Wilson RA, Walker KW, et al. Validation of an algorithm for predicting cardiac events in renal transplant candidates. Am J Cardiol 2002, 89:847-850.
81. Tadros GM, Herzog CA Percutaneous coronary intervention in chronic kidney disease patients. J Nephrol 2004, 17:364-368.
82. Jaeger JQ, Mehta RL Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol 1999, 10:392-403.
83. Journois D Hemofiltration during cardiopulmonary bypass. Kidney Int 1998, (Suppl 66):S174-S177.
84. van der Hoven B, van der Spoel JI, Scheffer GJ, et al. Intraoperative continuous hemofiltration for metabolic management in acute aortoiliac occlusion. J Clin Anesth 1998, 10:599-602.
85. Blackwell MM, Chavin KD, Sistino JJ, et al. Perioperative perfusion strategies for optimal fluid management in liver transplant recipients with renal insufficiency. Perfusion 2003, 18:55-60.
86. Gotti E, Mecca G, Valentino C, et al. Renal biopsy in patients with acute renal failure and prolonged bleeding time: A preliminary report. Am J Kidney Dis 1985, 6:397-399.
87. Bellomo R, Kellum J, Ronco C Acute renal failure: Time for consensus. Intensive Care Med 2001, 27:1685-1688.
88. Holt SG, Moore KP Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med 2001, 27:803-811.
89. Allison RC, Bedsole DL The other medical causes of rhabdomyolysis. Am J Med Sci 2003, 326:79-88.
90. Balogh Z, McKinley BA, Cox CS, et al. Abdominal compartment syndrome: The cause or effect of postinjury multiple organ failure. Shock 2003, 20:483-492.
91. Balogh Z, McKinley BA, Cocanour CS, et al. Patients with impending abdominal compartment syndrome do not respond to early volume loading. Am J Surg 2003, 186:602-607.
92. Shafi S, Kauder DR Fluid resuscitation and blood replacement in patients with polytrauma. Clin Orthop 2004, 37-42.
93. Godet G, Fleron MH, Vicaut E, et al. Risk factors for acute postoperative renal failure in thoracic or thoracoabdominal aortic surgery: A prospective study. Anesth Analg 1997, 85:1227-1232.
94. Levy EM, Viscoli CM, Horwitz RI The effect of acute renal failure on mortality: A cohort analysis. JAMA 1996, 275:1489-1494.
95. Chertow GM, Christiansen CL, Cleary PD, et al. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. Arch Intern Med 1995, 155:1505-1511.
96. Chertow GM, Levy EM, Hammermeister KE, et al. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998, 104:343-348.
97. Huynh TT, Miller CC, Estrera AL, et al. Determinants of hospital length of stay after thoracoabdominal aortic aneurysm repair. J Vasc Surg 2002, 35:648-653.
98. Lameire N, Vanholder R Pathophysiologic features and prevention of human and experimental acute tubular necrosis. J Am Soc Nephrol 2001, 12(Suppl 17):S20-S32.
99. Brezis M, Rosen S Hypoxia of the renal medulla its implications for disease. N Engl J Med 1995, 332:647-655.
100. Novis BK, Roizen MF, Aronson S, Thisted RA Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 1994, 78:143-149.
101. Wahbah AM, el-Hefny MO, Wafa EM, et al. Perioperative renal protection in patients with obstructive jaundice using drug combinations. Hepatogastroenterology 2000, 47:1691-1694.
102. Chew ST, Newman MF, White WD, et al. Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. Anesthesiology 2000, 93:325-331.
103. Rectenwald JE, Huber TS, Martin TD, et al. Functional outcome after thoracoabdominal aortic aneurysm repair. J Vasc Surg 2002, 35:640-647.
104. Wahlberg E, Dimuzio PJ, Stoney RJ, et al. Aortic clamping during elective operations for infrarenal disease: The influence of clamping time on renal function. J Vasc Surg 2002, 36:13-18.
105. Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med 2004, 351:1607-1618.
106. Bove T, Calabro MG, Landoni G, et al. The incidence and risk of acute renal failure after cardiac surgery. J Cardiothorac Vasc Anesth 2004, 18:442-445.
107. Chertow GM, Lazarus JM, Lew NL, et al. Preoperative renal risk stratification. Circulation 1997, 95:878-884.
108. Fortescue EB, Bates DW, Chertow GM Predicting acute renal failure after coronary bypass surgery: Cross-validation of two risk-stratification algorithms. Kidney Int 2000, 57:2594-2602.
109. Bucerius J, Gummert JF, Walther T, et al. On-pump versus off-pump coronary artery bypass grafting: Impact on postoperative renal failure requiring renal replacement therapy. Ann Thorac Surg 2004, 77:1250-1256.
110. Stallwood MI, Grayson AD, Mills K, Scawn ND Acute renal failure in coronary artery bypass surgery: Independent effect of cardiopulmonary bypass. Ann Thorac Surg 2004, 77:968-972.
111. Gamoso MG, Phillips-Bute B, Landolfo KP, et al. Off-pump versus on-pump coronary artery bypass surgery and postoperative renal dysfunction. Anesth Analg 2000, 91:1080-1084.
112. Schwann NM, Horrow JC, Strong MD, et al. Does off-pump coronary artery bypass reduce the incidence of clinically evident renal dysfunction after multivessel myocardial revascularization?. Anesth Analg 2004, 99:959-964.
113. Nathoe HM, van Dijk D, Jansen EW, et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 2003, 348:394-402.
114. Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 2000, 356:26-30.
115. Cole L, Bellomo R, Journois D, et al. High-volume haemofiltration in human septic shock. Intensive Care Med 2001, 27:978-986.
116. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730.
117. Rabbat CG, Thorpe KE, Russell JD, Churchill DN Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000, 11:917-922.
118. Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001, 12:589-597.
119. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000, 58:1311-1317.
120. Danovitch GM, Cecka JM Allocation of deceased donor kidneys: Past, present, and future. Am J Kidney Dis 2003, 42:882-890.
121. Ferreira SR, Moises VA, Tavares A, Pacheco-Silva A Cardiovascular effects of successful renal transplantation: A 1-year sequential study of left ventricular morphology and function and 24-hour blood pressure profile. Transplantation 2002, 74:1580-1587.
122. Nampoory MR, Das KC, Johny KV, et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 2003, 42:797-805.
123. United Network for Organ Sharing National kidney data Available at: http://www.unos.org.
124. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States 1988-1996. N Engl J Med 2001, 342:605-611.
125. Gonwa T, Johnson C, Ahsan N Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: Results at three years. Transplantation 2003, 75:2048-2053.
126. Johnson RWG Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens 2002, 11:603-607.
127. Goggins WC, Pascual MA, Powelson JA A prospective, randomized clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients [abstract]. Transplantation 2003, 76:798-802.
128. Szczech LA, Feldman HI Effect of anti-lymphocyte antibody induction therapy on renal allograft survival. Transplant Proc 1999, 31:9S-11S.
129. Luciani J, Frantz P, Thibault P, et al. Early anuria prevention in human kidney transplantation: Advantage of fluid load under pulmonary arterial pressure monitoring during surgical period. Transplantation 1979, 28:308-312.
130. Carlier M, Squifflet JP, Pirson Y, et al. Maximal hydration during anesthesia increases pulmonary arterial pressures and improves early function of human renal transplants. Transplantation 1982, 34:201-204.
131. Thomsen HS, Lokkegaard H, Munck O Influence of normal central venous pressure on onset of function in renal allografts. Scand J Urol Nephrol 1987, 21:143-145.
132. Dawidson IJ, Sandor ZF, Coorpender L, et al. Intraoperative albumin administration affects the outcome of cadaver renal transplantation. Transplantation 1992, 53:774-782.
133. Dawidson IJ, Ar'Rajab A Perioperative fluid and drug therapy during cadaver kidney transplantation. Clin Transpl 1992, 267-284.
134. Tiggeler RG, Berden JH, Hoitsma AJ, Koene RA Prevention of acute tubular necrosis in cadaveric kidney transplantation by the combined use of mannitol and moderate hydration. Ann Surg 1985, 201:246-251.
135. Van Valenberg PL, Hoitsma AJ, Tiggeler RG, et al. Mannitol as an indispensable constituent of an intraoperative hydration protocol for the prevention of acute renal failure after renal cadaveric transplantation. Transplantation 1987, 44:784-788.
136. Boldt J, Priebe HJ Intravascular volume replacement therapy with synthetic colloids: Is there an influence on renal function?. Anesth Analg 2003, 96:376-382.
137. Jubelirer SJ Hemostatic abnormalities in renal disease. Am J Kidney Dis 1985, 5:219-225.
138. Chen KS, Huang CC, Leu ML, et al. Hemostatic and fibrinolytic response to desmopressin in uremic patients. Blood Purif 1997, 15:84-91.
139. Davenport R Cryoprecipitate for uremic bleeding. Clin Pharm 1991, 10:429.
140. Gennari FJ, Segal AS Hyperkalemia: An adaptive response in chronic renal insufficiency. Kidney Int 2002, 62:1-9.
141. Michard F, Boussat S, Chemla D, et al. Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med 2000, 162:134-138.
142. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003, 348:5-14.
143. Schortgen, F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet 2001, 357:911-916.
144. Dehne MG, Muhling J, Sablotzki A, et al. Hydroxyethyl starch (HES) does not directly affect renal function in patients with no prior renal impairment. J Clin Anesth 2001, 13:103-111.
145. Boldt J New light on intravascular volume replacement regimens: What did we learn from the past three years?. Anesth Analg 2003, 97:1595-1604.
146. Ragaller MJ, Theilen H, Koch T Volume replacement in critically ill patients with acute renal failure. J Am Soc Nephrol 2001, 12(Suppl 17):S33-S39.
147. Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anesthesia in patients with end-stage renal disease. Br J Anesth 1998, 81:854-860.
148. Goyal P, Puri GD, Panday CK, Srivastva S Evaluation of induction doses of propofol: Comparison between endstage renal disease and normal renal function patients. Anesth Intensive Care 2002, 30:584-587.
149. Coriat P, Richer C, Douraki T, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology 1994, 81:299-307.
150. Pedraz JL, Lanao JM, Dominguez-Gil A Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function. Eur J Drug Metab Pharmacokinet 1985, 10:33-39.
151. Thapa S, Brull SJ Succinylcholine-induced hyperkalemia in patients with renal failure: An old question revisited. Anesth Analg 2000, 91:237-241.
152. Schow AJ, Lubarsky DA, Olson RP, Gan TJ Can succinylcholine be used safely in hyperkalemic patients?. Anesth Analg 2002, 95:119-122.
153. Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth 2000, 85:717-723.
154. Cooper RA, Mirakhur RK, Wierda JM, Maddineni VR Pharmacokinetics of rocuronium bromide in patients with and without renal failure. Eur J Anesthesiol 1995, 11:43-44.
155. Murray MJ, Coursin DB, Scuderi PE, et al. Double-blind, randomized, multicenter study of doxacurium vs. pancuronium in intensive care unit patients who require neuromuscular-blocking agents. Crit Care Med 1995, 23:450-458.
156. Sakamoto H, Takita K, Kemmotsu O, et al. Increased sensitivity to vecuronium and prolonged duration of its action in patients with end-stage renal failure. J Clin Anesth 2001, 13:193-197.
157. Fisher DM, Reynolds KS, Schmith VD, et al. The influence of renal function on the pharmacokinetics and pharmacodynamics and simulated time course of doxacurium. Anesth Analg 1997, 89:786-795.
158. Kisor DF, Schmith VD, Wrgin WA, et al. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996, 83:1065-1071.
159. Lien CA, Schmith VD, Belmont MR, et al. Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1996, 84:300-308.
160. Bevan DR, Archer D, Donati F, et al. Antagonism of pancuronium in renal failure: No recurarization. Br J Anaesth 1982, 54(1):63-68.
161. Dhonneur G, Rebaine C, Slavov V, et al. Neostigmine reversal of vecuronium neuromuscular block and the influence of renal failure. Anesth Analg 1996, 82:134-138.
162. D'Honneur G, Gilton A, Sandouk P, et al. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine: The influence of renal failure. Anesthesiology 1994, 81:87-93.
163. Lotsch J, Zimmermann M, Darimont J, et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology 2002, 97:814-819.
164. Angst MS, Buhrer M, Lotsch J Insidious intoxication after morphine treatment in renal failure: Delayed onset of morphine-6-glucuronide action. Anesthesiology 2002, 92:1473-1476.
165. Al-Khafaji AH, Dewhirst WE, Manning HL, et al. Propylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis. Anesth Analg 2002, 94:1583-1585. table of contents.
166. Dahaba AA, von Klobucar F, Rehak PH, List WF Total intravenous anesthesia with remifentanil, propofol and cisatracurium in end-stage renal failure. Can J Anaesth 1999, 46:696-700.
167. Basta M, Sloan P Epidural hematoma following epidural catheter placement in a patient with chronic renal failure. Can J Anaesth 1999, 46:271-274.
168. Mazze RI, Shue GL, Jackson SH Renal dysfunction associated with methoxyflurane anesthesia: A randomized, prospective clinical evaluation. JAMA 1971, 216:278-288.
169. Barr GA, Cousins MJ, Mazze RI, et al. A comparison of the renal effects and metabolism of enflurane and methoxyflurane in Fischer 344 rats. J Pharmacol Exp Ther 1974, 188:257-264.
170. Mazze RI, Trudell JR, Cousins MJ Methoxyflurane metabolism and renal dysfunction: Clinical correlation in man. Anesthesiology 1971, 35:247-252.
171. Litz RJ, Hubler M, Lorenz W, et al. Renal responses to desflurane and isoflurane in patients with renal insufficiency. Anesthesiology 2002, 97:1133-1136.
172. Spencer EM, Willatts SM, Prys-Roberts C Plasma inorganic fluoride concentrations during and after prolonged (> 24 hr) isoflurane sedation: Effect on renal function. Anesth Analg 1991, 73:731-737.
173. Kong KL, Tyler JE, Willatts SM, Prys-Roberts C Isoflurane sedation for patients undergoing mechanical ventilation: Metabolism to inorganic fluoride and renal effects. Br J Anaesth 1990, 64:159-162.
174. Taves DR, Fry BW, Freeman RB, Gillies AJ Toxicity following methoxyflurane anesthesia: II. Fluoride concentrations in nephrotoxicity. JAMA 1970, 214:91-95.
175. Cittanova, ML, Lelongt B, Verpont MC, et al. Fluoride ion toxicity in human kidney collecting duct cells. Anesthesiology 1996, 84:428-435.
176. Cousins MJ, Mazze RI Methoxyflurane nephrotoxicity: A study of dose response in man. JAMA 1973, 225:1611-1616.
177. Kobayashi Y, Ochiai R, Takeda J, et al. Serum and urinary inorganic fluoride concentrations after prolonged inhalation of sevoflurane in humans. Anesth Analg 1992, 74:753-757.
178. Frink EJ, Ghantous H, Malan TP, et al. Plasma inorganic fluoride with sevoflurane anesthesia: Correlation with indices of hepatic and renal function. Anesth Analg 1992, 74:231-235.
179. Eger EI, Gong D, Koblin DD, et al. Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers. Anesth Analg 1997, 85:1154-1163.
180. Frink EJ, Ghantous H, Malan TP, et al. Plasma inorganic fluoride with sevoflurane anesthesia: Correlation with indices of hepatic and renal function. Anesth Analg 1992, 74:231-235.
181. 2O anesthesia. Anesth Analg 1992, 74:253-259.
182. Hara T, Fukusaki M, Nakamura T, Sumikawa K Renal function in patients during and after hypotensive anesthesia with sevoflurane. J Clin Anesth 1998, 10:539-545.
183. Kharasch ED, Hankins DC, Thummel KE Human kidney methoxyflurane and sevoflurane metabolism: Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 1995, 82:689-699.
184. Gonsowski CT, Laster MJ, Eger EI, et al. Toxicity of compound A in rats: Effect of increasing duration of administration. Anesthesiology 1994, 80:566-573.
185. Mazze RI, Callan CM, Galvez ST, et al. The effects of sevoflurane on serum creatinine and blood urea nitrogen concentrations: A retrospective, twenty-two-center, comparative evaluation of renal function in adult surgical patients. Anesth Analg 2000, 90:683-688.
186. Conzen PF, Nuscheler M, Melotte A, et al. Renal function and serum fluoride concentrations in patients with stable renal insufficiency after anesthesia with sevoflurane or enflurane. Anesth Analg 1995, 81:569-575.
187. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993, 341:335-339.
188. Walsh TJ, Finberg RW, Amdt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999, 340:764-771.
189. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002, 346:225-234.
190. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004, 44:1393-1399.
191. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994, 331:1416-1420.
192. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343:180-184.
193. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002, 62:2202-2207.
194. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004, 291:2328-2334.
195. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003, 349:1333-1340.
196. DeBroe ME, Elseviers MM Analgesic nephropathy. N Engl J Med 1998, 338:446-452.
197. Ronco PM Drug-induced end-stage renal disease. N Engl J Med 1994, 331:1711-1712.
198. Sivarajan M, Wasse L Perioperative acute renal failure associated with preoperative intake of ibuprofen. Anesthesiology 1997, 86:1390-1392.
199. Jaquenod M, Ronnhedh C, Cousins MJ, et al. Factors influencing ketorolac-associated perioperative renal dysfunction. Anesth Analg 1998, 86:1090-1097.
200. Laisalmi M, Teppo AM, Kovusalo AM, et al. The effect of ketorolac and sevoflurane anesthesia on renal glomerular and tubular function. Anesth Analg 2001, 93:1210-1213.
201. Fredman B, Zohar E, Golan E, et al. Diclofenac does not decrease renal blood flow or glomerular filtration in elderly patients undergoing orthopedic surgery. Anesth Analg 1999, 88:149-154.
202. McCrory CR, Lindahl SGE Cyclooxygenase inhibition for perioperative analgesia. Anesth Analg 2002, 95:169-176.
203. Licker M, Bednarkiewicz M, Neidhart P, et al. Preoperative inhibition of angiotensin-converting enzyme improves systemic and renal haemodynamic changes during aortic abdominal surgery. Br J Anaesth 1996, 76:632-639.
204. Coriat P, Richer C, Douraki T, et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology 1994, 81:299-307.
205. Bertrand M, Godet G, Meersschaert K, et al. Should the angiotensin II antagonists be discontinued before surgery?. Anesth Analg 2001, 92:26-30.
206. Ryckwaert F, Colson P, Andre E, et al. Haemodynamic effects of an angiotensin-converting enzyme inhibitor and angiotensin receptor
207. Cittanova ML, Zubicki A, Savu C, et al. The chronic inhibition of angiotensin-converting enzyme impairs postoperative renal function. Anesth Analg 2001, 93:1111-1115.
208. Bello-Reuss E, Higashi Y, Kaneda Y Dopamine decreases fluid reabsorption in straight portions of rabbit proximal tubule. Am J Physiol 1982, 242:F634-F640.
209. Lassnigg A, Donner E, Grubhofer G, et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000, 11:97-104.
210. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000, 356:2139-2143.
211. Conger JD Interventions in clinical acute renal failure: What are the data?. Am J Kidney Dis 1995, 26:565-576.
212. Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002, 288:2547-2553.
213. Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004, 32:1669-1677.
214. Piper SN, Kumle B, Maleck WH, et al. Diltiazem may preserve renal tubular integrity after cardiac surgery. Can J Anesth 2003, 50:285-292.
215. Carpenter JP, Fairman RM, Barker CF, et al. Endovascular AAA repair in patients with renal insufficiency: Strategies for reducing adverse renal events. Cardiovasc Surg 2001, 9:559-564.